Protocol Ledger

NCT06738485 · Phase III · COMPLETED

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

Interventional Phase III clinical trial protocol NCT06738485 sponsored by CSL Behring in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-09 Enrollment: 62 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06738485
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)62 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06738485
Protocol FieldVerified Registry Value
NCT IdentifierNCT06738485
Consolidated Lead SponsorCSL Behring
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment62 participants (ACTUAL)
Registered Start Date2025-01-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI